Evidence map›Paper›PMID 41022699›Full record

ArticleNature communications2025

Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties.

Kristin Hovden Aaen, Maria Francesca Testa, Jeannette Nilsen, Rebecca Tarantino, Cesare Canepari, Mascia Benedusi, Sopisa Benjakul, Mari Nyquist-Andersen, Marie Leangen Herigstad, Alessio Cantore and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Extravascular factor IX: a semicentennial narrative review.Research and practice in thrombosis and haemostasis · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kristin Hovden Aaen *Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-7181-1052
Maria Francesca Testa *Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Jeannette NilsenInstitute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.
Rebecca TarantinoDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Cesare CanepariSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Mascia BenedusiDepartment of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.
Sopisa BenjakulInstitute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0003-3708-8125
Mari Nyquist-AndersenInstitute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-5248-6722
Marie Leangen HerigstadInstitute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.
Alessio CantoreSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-9741-997X
Giuseppe ValacchiDepartment of Environmental Sciences and Prevention, University of Ferrara, Ferrara, Italy.
Inger SandlieDepartment of Biosciences, University of Oslo, Oslo, Norway.
Francesco BernardiDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Mirko PinottiDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Alessio BranchiniDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. brnlss@unife.it.ORCID http://orcid.org/0000-0002-6113-2694
Jan Terje AndersenInstitute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway. j.t.andersen@medisin.uio.no.ORCID http://orcid.org/0000-0003-1710-1628

Funding

Kreftforeningen (Norwegian Cancer Society) 223315Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2024046Norges Forskningsråd (Research Council of Norway) 274993; 332727Norges Forskningsråd (Research Council of Norway) 287927; 332727Norges Forskningsråd (Research Council of Norway) 332727
6 · The paper itself

Abstract

The efficacy of hemophilia B (HB) replacement therapy is evaluated by coagulation factor IX (FIX) activity in plasma, although FIX bound to extravascular type IV collagen (Col4) also contributes to efficient hemostasis. Here, we investigated the impact of engineering FIX for improved (K5R) or reduced (K5A) Col4 binding on the pharmacokinetic properties of FIX Padua, fused to human serum albumin (HSA

Indexed as

CollagenCollagen Type IVFactor IXHemophilia BRecombinant Fusion ProteinsSerum Albumin, HumanAnimalsHalf-LifeHistocompatibility Antigens Class IHumansMaleMiceMice, Inbred C57BLProtein BindingProtein EngineeringReceptors, FcCollagenCollagen Type IVFactor IXFc receptor, neonatalHistocompatibility Antigens Class IReceptors, FcRecombinant Fusion ProteinsSerum Albumin, Human

Identifiers

PMID41022699
PMCPMC12480940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.